 Recently, Regorafenib has shown efficacy in patients pretreated with all these options in a large phase III trial, where it prolonged OS compared with placebo Grothey, et al 2013. In addition, the results were confirmed in a smaller randomised trial in the Asian population, with patients being less intensively pre-treated Li et al, 2014. Therefore, regorafenib is now considered a standard option in pre-treated patients. 